Free tool
FAERS Monitor: Lotensin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019851 or its brand name (Lotensin, Benazepril Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,351
Serious
4,638
63% of reports
Hospitalization
2,498
Death reported
582
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea454
- drug ineffective431
- fatigue414
- dizziness401
- dyspnoea387
- diarrhoea367
- pain365
- headache357
- myocardial infarction311
- hypertension303
- asthenia274
- cough266
- vomiting263
- anxiety253
- cerebrovascular accident250
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 305 |
| 2005 | 352 |
| 2006 | 419 |
| 2007 | 320 |
| 2008 | 327 |
| 2009 | 511 |
| 2010 | 637 |
| 2011 | 699 |
| 2012 | 537 |
| 2013 | 191 |
| 2014 | 406 |
| 2015 | 288 |
| 2016 | 278 |
| 2017 | 311 |
| 2018 | 266 |
| 2019 | 193 |
| 2020 | 130 |
| 2021 | 151 |
| 2022 | 210 |
| 2023 | 175 |
| 2024 | 193 |
| 2025 | 168 |
| 2026 | 283 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,808 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myocardial infarctionSignal | 311 | 5.1 | 4.6 | 1,030 |
| cerebrovascular accidentSignal | 250 | 4.2 | 3.7 | 617 |
| hypertensionSignal | 303 | 4.1 | 3.7 | 713 |
| coughSignal | 266 | 2.7 | 2.4 | 290 |
| anxietySignal | 253 | 2.5 | 2.3 | 239 |
| dizzinessSignal | 401 | 2.3 | 2.1 | 301 |
| astheniaSignal | 274 | 2.1 | 1.9 | 156 |
| dyspnoea | 387 | 2.0 | 1.8 | 185 |
| pain | 365 | 1.7 | 1.5 | 108 |
| nausea | 454 | 1.6 | 1.5 | 118 |
| headache | 357 | 1.6 | 1.5 | 89 |
| diarrhoea | 367 | 1.6 | 1.5 | 91 |
| vomiting | 263 | 1.6 | 1.4 | 60 |
| fatigue | 414 | 1.5 | 1.4 | 76 |
| drug ineffective | 431 | 0.9 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.